Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05626114 · ClinicalTrials.gov registry record · Phase 2
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
A Phase 2 study of Geographic Atrophy, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 17
- Study locations
NCT05626114: Recruiting Phase 2 study of Geographic Atrophy, sponsored by Genentech.
NCT05626114 is a Phase 2 study of Geographic Atrophy that is actively recruiting participants, run by Genentech. The registered enrollment target is 60 participants, below the 220-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (73% lower). The trial reports 17 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05626114, a Phase 2 study of Geographic Atrophy, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 17
- Study locations
Study Summary
This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated. The substudy will evaluate the operational feasibility and scientific interpretability of incorporating AO retinal imaging using the EarlySight Cellularis® Discovery device. Participants who have fulfilled the eligibility requirements for the parent study and meet the substudy's eligibility criteria will have the option to participate in the substudy. The EarlySight Cellularis® Discovery device will be used only as an assessment tool and data obtained from this device will not be used to guide clinical care or influence clinical outcomes for participants.
Conditions Studied
Interventions
- BIOLOGICAL OpRegen
Study Locations (17)
California
- Retina-Vitreous Associates Medical Group - Beverly Hills
- Retinal Consultants Medical Group - Sacramento
- West Coast Retina - San Francisco
Texas
- Austin Clinical Research, LLC - Austin
- Retina Consultants of Texas - Bellaire
Other
- Hadassah MC - Jerusalem
- Tel Aviv Sourasky MC - Tel Aviv
Florida
- Retina Vitreous Associates of Florida - St. Petersburg
Maryland
- The Retina Care Center - Baltimore
Missouri
- The Retina Institute - St Louis
Nevada
- Sierra Eye Associates - Reno
North Carolina
- Duke Eye Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-03-23 |
| Est. Completion | 2031-03-01 |
| Phase | Phase 2 |
What NCT05626114 shows while recruiting
NCT05626114 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 220-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Geographic Atrophy appearing as the primary indexed condition, and to 1 intervention - of which OpRegen is the first listed.
NCT05626114 lists 17 locations in 13 states (California, Texas, Other).
Frequently Asked Questions
What is clinical trial NCT05626114 about?
NCT05626114 is a clinical study titled "A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251". This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated. T...
What is the current status of trial NCT05626114?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-03-23. Estimated completion is 2031-03-01.
What conditions does trial NCT05626114 study?
This clinical trial studies the following conditions: Geographic Atrophy.
What interventions are being tested in trial NCT05626114?
The interventions under investigation include: OpRegen (BIOLOGICAL).
Who is sponsoring clinical trial NCT05626114?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05626114 being conducted?
This trial has 17 study locations across California, Florida, Maryland, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05626114's enrollment target sits among peer trials
60 20th of 27 higher than 6 of 27 other Geographic Atrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Geographic Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RECRUITING · Phase 2
-
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI